Lead Product(s) : Nefopam Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Maxona Pharmaceuticals Announces MAX-OO1 Phase 1 Clinical Program Results
Details : MAX-001 (Nefopam HCl) is a non-opioid, non-NSAID oral therapy, which is currently being evaluated for the treatment of patients with acute and chronic pain.
Product Name : MAX-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 18, 2025
Lead Product(s) : Nefopam Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
